Phase II Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair Genes
Summary
The purpose of this phase II, open-label, single-arm trial is to evaluate the response of rucaparib in patients with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes.
General Information
NCT#: NCT04171700
Study ID: CO-338-100
Trial Phase: Phase II
Trial Sponsor: Clovis Oncology
Therapies Used in This Trial: Rucaparib